Product nameAnti-CX3CL1 antibody
See all CX3CL1 primary antibodies
DescriptionRabbit polyclonal to CX3CL1
Tested applicationsSuitable for: ICC/IF, IHC-FoFr, IHC-Fr, IHC-P, WBmore details
Species reactivityReacts with: Mouse, Rat, Human
Recombinant fragment: E. coli expressed chemotactic domain of human CX3CL1
- WB: Mouse recombinant protein. IHC-P: Human lung tissue. ICC/IF: HeLa cells.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.1% Sodium azide
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab25088 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 1 µg/ml.|
|IHC-FoFr||Use at an assay dependent concentration. PubMed: 22387113|
|IHC-Fr||1/100 - 1/500.|
|IHC-P||Use a concentration of 4 µg/ml.|
|WB||1/1000 - 1/5000. Predicted molecular weight: 42 kDa.|
FunctionThe soluble form is chemotactic for T-cells and monocytes, but not for neutrophils. The membrane-bound form promotes adhesion of those leukocytes to endothelial cells. May play a role in regulating leukocyte adhesion and migration processes at the endothelium. Binds to CX3CR1.
Tissue specificitySmall intestine, colon, testis, prostate, heart, brain, lung, skeletal muscle, kidney and pancreas.
Sequence similaritiesBelongs to the intercrine delta family.
modificationsA soluble short 95 kDa form may be released by proteolytic cleavage from the long membrane-anchored form.
O-glycosylated with core 1 or possibly core 8 glycans.
Cellular localizationSecreted and Cell membrane.
- Information by UniProt
- A 152E5.2 antibody
- AB030188 antibody
- ABCD 3 antibody
Anti-CX3CL1 antibody (ab25088) at 1/1000 dilution + mouse recombinant protein at 0.025 µg
HRP conjugated goat anti-rabbit at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 42 kDa
Observed band size: 90 kDa why is the actual band size different from the predicted?
Exposure time: 1 minute
The gel running conditions were denaturing.
The membrane was blocked with 10% milk for 30 minutes at RT and the primary antibody was incubated with the membrane for 16 hours at 4°C
ab25088 (4µg/ml) staining CX3CL1 in human lung using an automated system (DAKO Autostainer Plus). Using this protocol there is staining of the cytoplasmic region of the cells.
Sections were rehydrated and antigen retrieved with the Dako 3 in 1 AR buffers EDTA pH 9.0 in a DAKO PT link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 mins. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 min and detected with Dako envision flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that, for manual staining, optimization of primary antibody concentration and incubation time is recommended. Signal amplification may be required.
ICC/IF image of ab25088 stained HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab25088, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
This product has been referenced in:
- Senouthai S et al. Fractalkine is Involved in Lipopolysaccharide-Induced Podocyte Injury through the Wnt/ß-Catenin Pathway in an Acute Kidney Injury Mouse Model. Inflammation N/A:N/A (2019). Read more (PubMed: 30919150) »
- Liu P et al. CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway. Int J Oncol 53:1544-1556 (2018). Read more (PubMed: 30066854) »